Association of decreased expression of long non-coding RNA LOC285194 with chemoradiotherapy resistance and poor prognosis in esophageal squamous cell carcinoma

Journal of Translational Medicine

Xiu-feng Cao⁴  Bin Zhu⁴  Jin-song Yang²  Jin Lv⁴  Tong-xin Yang⁴  Qing-quan Wu³  Xiao-wei Wang⁵  Xi-lei Zhou¹  Yu-suo Tong⁴ 

[1] Department of Radiation Oncology, Affiliated Huai¿an First Hospital of Nanjing Medical University, Huai¿an, Jiangsu, China;Department of Medical Oncology, Affiliated Nanjing Hospital of Nanjing Medical University and Oncology Center of Nanjing Medical University, Nanjing, Jiangsu, China;Department of Thoracic Surgery, Affiliated Huai¿an First Hospital of Nanjing Medical University, Huai¿an, Jiangsu, China;Department of Surgical Oncology, Affiliated Nanjing Hospital of Nanjing Medical University and Oncology Center of Nanjing Medical University, Nanjing, Jiangsu, China;Department of Medical Oncology, Affiliated Huai¿an First Hospital of Nanjing Medical University, Huai¿an, Jiangsu, China

关键词: Prognosis;    Chemoradiotherapy;    LOC285194;    Long non-coding RNA;    Esophageal squamous cell carcinoma;   

Others  :  1148350
DOI  :  10.1186/s12967-014-0233-y

 received in 2014-03-30, accepted in 2014-08-18,  发布年份 2014

【 摘 要 】

Background

Expression of the long non-coding RNA (lncRNA) LOC285194 was previously shown to be correlated with aggressive clinicopathological features and poor prognosis in several cancers. The aim of the present study was to explore the relationship between LOC285194 expression and clinical outcomes in esophageal squamous cell carcinoma (ESCC), so as to assess whether it could be a novel biomarker for prognosis and prediction of response to therapy on ESCC patients.

Methods

The method of quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure LOC285194 expression in pretreatment biopsy specimens and matched normal tissue derived from ESCC patients who underwent preoperative chemoradiotherapy followed by surgical resection (CRT?+?S group; n =?55) or from those who received surgical resection alone (S group; n =?87). The association between LOC285194 expression and clinicopathological features and prognosis were then analyzed.

Results

LOC285194 expression was significantly down-regulated in ESCC tumor tissues when compared with the adjacent normal tissues (p <?0.001). Low expression of LOC285194 was associated with larger tumor size (p =?0.002), advanced TNM stage (p =?0.018), more lymph node metastases (p =?0.013) and distant metastases (p =?0.015). In the CRT?+?S group, the pathological complete response rate was 57% (16/28) for the LOC285194-high group, and 15% (4/27) for the LOC285194-low group. Univariate analysis revealed that low expression of LOC285194 was significantly correlated with CRT response (p =?0.002). Moreover, Kaplan-Meier survival analysis revealed that patients with low expression of LOC285194 had a decreased disease free survival (DFS) (p <?0.001) and overall survival (OS) (p <?0.001). Multivariable analysis further identified low expression of LOC285194 as an independent prognosis factor for CRT response (p =?0.011), DFS (p <?0.001) and OS (p =?0.002).

Conclusion

Decreased expression of LOC285194 could serve as a molecular marker to predict the clinical outcome of ESCC patients after surgery, and select patients who would benefit from preoperative CRT.

【 授权许可】

   
2014 Tong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [2]Sarbia M, Ott N, Pühringer-Oppermann F, Brücher BL: The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus. Br J Cancer 2007, 97:1404-1408.
• [3]Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, Ajani JA: Association of activated transcription factor nuclear factor B with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006, 24:748-754.
• [4]van Hagen P1, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012, 366:2074-2084.
• [5]Berger AC1, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005, 23:4330-4337.
• [6]Rohatgi P1, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, Ajani JA: Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005, 104:2365-2372.
• [7]Qi P, Du X: The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol 2013, 26:155-165.
• [8]Li CH, Chen Y: Targeting long non-coding RNAs in cancers: Progress and prospects. Int J Biochem Cell Biol 2013, 45:1895-1910.
• [9]Chen FJ1, Sun M, Li SQ, Wu QQ, Ji L, Liu ZL, Zhou GZ, Cao G, Jin L, Xie HW, Wang CM, Lv J, De W, Wu M, Cao XF: Upregulation of the long non-coding rna hotair promotes esophageal squamous cell carcinoma metastasis and poor prognosis. Mol Carcinog 2013, 52:908-915.
• [10]Gupta RA1, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464:1071-1076.
• [11]Gutschner T1, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, Zörnig M, MacLeod AR, Spector DL, Diederichs S: The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 2013, 73:1180-1189.
• [12]Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K: Characterization of HULC, a novel gene with striking Up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007, 132:330-342.
• [13]Spizzo R, Almeida MI, Colombatti A, Calin GA: Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene 2012, 31:4577-4587.
• [14]Pasic I1, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, Novokmet A, Malkin D: Recurrent focal copy-number changes and loss of heterozygosity implicate Two noncoding RNAs and One tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Cancer Res 2010, 70:160-171.
• [15]Liu Q1, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, Wu F, Mo YY: LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res 2013, 41:4976-4987.
• [16]Qi P, Xu MD, Ni SJ, Huang D, Wei P, Tan C, Zhou XY, Du X: Low expression of LOC285194 is associated with poor prognosis in colorectal cancer. J Transl Med 2013, 11:122. BioMed Central Full Text
• [17]Chirieac LR1, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT: Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005, 103:1347-1355.
• [18]He LR1, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ, Chen YC, Zhang LJ, Guan XY, Zeng YX, Kung HF, Xie D: High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer 2010, 127:138-147.
• [19]Wapinski O, Chang HY: Long noncoding RNAs and human disease. Trends Cell Biol 2011, 21:354-361.
• [20]Asuthkar S1, Velpula KK, Chetty C, Gorantla B, Rao JS: Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncol Target 2012, 3:1439-1454.
• [21]Gao H1, Wang LD, Zhou Q, Hong JY, Huang TY, Yang CS: p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res 1994, 54:4342-4346.
• [22]Abedi-Ardekani B1, Kamangar F, Sotoudeh M, Villar S, Islami F, Aghcheli K, Nasrollahzadeh D, Taghavi N, Dawsey SM, Abnet CC, Hewitt SM, Fahimi S, Saidi F, Brennan P, Boffetta P, Malekzadeh R: Extremely high Tp53 mutation load in esophageal squamous cell carcinoma in Golestan Province, Iran. PLoS One 2011, 6:e29488.
• [23]Ito T1, Kaneko K, Makino R, Ito H, Konishi K, Kurahashi T, Kitahara T, Mitamura K: Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitivechemoradiotherapy. J Gastroenterol 2001, 36:303-311.
• [24]Akutsu Y, Hanari N, Yusup G, Komatsu-Akimoto A, Ikeda N, Mori M, Yoneyama Y, Endo S, Miyazawa Y, Matsubara H: COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol 2011, 18:2946-2951.
• [25]Courrech Staal EF1, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW: Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 2010, 97:1482-1496.
• [26]Forbes SA1, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR: The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Proloc Hum Genet 2008, Chater 10:unit 10.11.
• [27]Shimada H1, Takeda A, Nabeya Y, Okazumi SI, Matsubara H, Funami Y, Hayashi H, Gunji Y, Kobayashi S, Suzuki T, Ochiai T: Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001, 92:663-669.
• [28]Brücher BL1, Keller G, Werner M, Müller U, Lassmann S, Cabras AD, Fend F, Busch R, Stein H, Allescher HD, Molls M, Siewert JR, Höfler H, Specht K: Using Q-RT-PCR to measure cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. Int J Colorectal Dis 2008, 24:69-77.